Literature DB >> 31055969

Increased Protein Insolubility in Brains From a Subset of Patients With Schizophrenia.

Leslie G Nucifora1, Matthew L MacDonald1, Brian J Lee1, Matthew E Peters1, Alexis L Norris1, Benjamin C Orsburn1, Kun Yang1, Kelly Gleason1, Russell L Margolis1, Jonathan Pevsner1, Carol A Tamminga1, Robert A Sweet1, Christopher A Ross1, Akira Sawa1, Frederick C Nucifora1.   

Abstract

OBJECTIVE: The mechanisms leading to schizophrenia are likely to be diverse. However, there may be common pathophysiological pathways for subtypes of the disease. The authors tested the hypothesis that increased protein insolubility and ubiquitination underlie the pathophysiology for a subtype of schizophrenia.
METHODS: Prefrontal cortex and superior temporal gyrus from postmortem brains of individuals with and without schizophrenia were subjected to cold sarkosyl fractionation, separating proteins into soluble and insoluble fractions. Protein insolubility and ubiquitin levels were quantified for each insoluble fraction, with normalization to total homogenate protein. Mass spectrometry analysis was then performed to identify the protein contents of the insoluble fractions. The potential biological relevance of the detected proteins was assessed using Gene Ontology enrichment analysis and Ingenuity Pathway Analysis.
RESULTS: A subset of the schizophrenia brains showed an increase in protein insolubility and ubiquitination in the insoluble fraction. Mass spectrometry of the insoluble fraction revealed that brains with increased insolubility and ubiquitination exhibited a similar peptide expression by principal component analysis. The proteins that were significantly altered in the insoluble fraction were enriched for pathways relating to axon target recognition as well as nervous system development and function.
CONCLUSIONS: This study suggests a pathological process related to protein insolubility for a subset of patients with schizophrenia. Determining the molecular mechanism of this subtype of schizophrenia could lead to a better understanding of the pathways underlying the clinical phenotype in some patients with major mental illness as well as to improved nosology and identification of novel therapeutic targets.

Entities:  

Keywords:  Aggregation; Protein Insolubility; Protein Misfolding; Schizophrenia; Subtype; Ubiquitination

Mesh:

Substances:

Year:  2019        PMID: 31055969     DOI: 10.1176/appi.ajp.2019.18070864

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  12 in total

1.  Research Domain Criteria: Strengths, Weaknesses, and Potential Alternatives for Future Psychiatric Research.

Authors:  Christopher A Ross; Russell L Margolis
Journal:  Mol Neuropsychiatry       Date:  2019-08-13

Review 2.  A Perspective on the Potential Involvement of Impaired Proteostasis in Neuropsychiatric Disorders.

Authors:  Kelvin K Hui; Ryo Endo; Akira Sawa; Motomasa Tanaka
Journal:  Biol Psychiatry       Date:  2021-09-14       Impact factor: 13.382

3.  PTMs: A Missing Piece for Schizophrenia Studies.

Authors:  Caroline Brandão-Teles; Bradley J Smith; Victor Corasolla Carregari
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

4.  Molecular origin of somatostatin-positive neuron vulnerability.

Authors:  Toshifumi Tomoda; Akiko Sumitomo; Dwight Newton; Etienne Sibille
Journal:  Mol Psychiatry       Date:  2022-02-10       Impact factor: 13.437

Review 5.  Neuronal Autophagy in Synaptic Functions and Psychiatric Disorders.

Authors:  Toshifumi Tomoda; Kun Yang; Akira Sawa
Journal:  Biol Psychiatry       Date:  2019-07-29       Impact factor: 13.382

6.  Glutamatergic hypo-function in the left superior and middle temporal gyri in early schizophrenia: a data-driven three-dimensional proton spectroscopic imaging study.

Authors:  Juan R Bustillo; Joel Upston; Elizabeth Grace Mayer; Thomas Jones; Andrew A Maudsley; Charles Gasparovic; Mauricio Tohen; Rhoshel Lenroot
Journal:  Neuropsychopharmacology       Date:  2020-05-13       Impact factor: 7.853

7.  Overlapping Genetic Architecture Between Schizophrenia and Neurodegenerative Disorders.

Authors:  Chunyu Li; Tianmi Yang; Ruwei Ou; Huifang Shang
Journal:  Front Cell Dev Biol       Date:  2021-12-24

8.  Neutrophil-to-Lymphocyte Ratio Is Independently Associated With Severe Psychopathology in Schizophrenia and Is Changed by Antipsychotic Administration: A Large-Scale Cross-Sectional Retrospective Study.

Authors:  Xia Zhou; Xiaolan Wang; Rui Li; Jun Yan; Ying Xiao; Weiguang Li; Hong Shen
Journal:  Front Psychiatry       Date:  2020-10-30       Impact factor: 4.157

9.  Lack of Support for the Genes by Early Environment Interaction Hypothesis in the Pathogenesis of Schizophrenia.

Authors:  Evangelos Vassos; Jiaqi Kou; Sarah Tosato; Jessye Maxwell; Charlotte A Dennison; Sophie E Legge; James T R Walters; Michael J Owen; Michael C O'Donovan; Gerome Breen; Cathryn M Lewis; Patrick F Sullivan; Christina Hultman; Mirella Ruggeri; Muriel Walshe; Elvira Bramon; Sarah E Bergen; Robin M Murray
Journal:  Schizophr Bull       Date:  2022-01-21       Impact factor: 9.306

Review 10.  Investigating Post-translational Modifications in Neuropsychiatric Disease: The Next Frontier in Human Post-mortem Brain Research.

Authors:  Melanie J Grubisha; Robert A Sweet; Matthew L MacDonald
Journal:  Front Mol Neurosci       Date:  2021-07-16       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.